Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the level of cytokines (which are small proteins important in cell signalling) in eye fluid (aqueous humour) in patients with wet age related macular degeneration patients who have been treated with an injection in the eye (intravitreal injection) with a drug called ranibizumab. The level of cytokines will be compared between patients who have a good response to ranibizumab treatment and patients who are non-responsive to ranibizumab and need other forms of therapy. This knowledge will help for the future treatment and to potentially develop new medication for wet age-related macular degeneration.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Aflibercept; Ranibizumab

Criteria

Inclusion Criteria:

• Age 50 years or more

• Ranibizumab resistance/poor responder patients in all AMD entities (typical AMD, PCV and RAP) who will be treated with intravitreous ranibizumab in combination with verteporfin photodynamic therapy

• Ranibizumab resistance/poor responder patients in all AMD entity (typical AMD, PCV and RAP) who will be treated with intravitreous aflibercept injection

• AMD patient who is good response to the treatment of ranibizumab (control group)

Exclusion Criteria:

• Any evidence of good response in treatment of ranibizumab,

• Uncooperative patients to intravitreal treatment

• Patients who have clinically active ocular inflammation

• Patients who have previous PDT treatment within 6 months

• Patient who previously have ocular treatment of immunosuppressive agent within 3 months

• Patient who previously have ocular treatment of steroid with in 3 months

• Patients who are currently on systemic treatment of anti-VEGF medication or immunosuppressive agents.